Effects of the Cyclooxygenase Inhibiting Nitric Oxide Donator Naproxcinod Versus Naproxen on Systemic Blood Pressure in Patients With Osteoarthritis

American Journal of Cardiology

Volumn 104, Issue 6, 2009, Pages 840-845

  White, William B ^a   Schnitzer, Thomas J ^b   Fleming, Rosanna ^c,d   Duquesroix, Brigitte ^c,d   Beekman, Maarten ^c,d  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c NicOx SA   (France)

^d NicOx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIURETIC AGENT; N(G) NITROARGININE METHYL ESTER; NAPROXCINOD; NAPROXEN; NITRIC OXIDE DONOR; PLACEBO; PROSTAGLANDIN SYNTHASE INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SYSTOLIC BLOOD PRESSURE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD PRESSURE; COMORBIDITY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS;

EID: 69449105980     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.05.014     Document Type: Article

References (20)

1. Schnitzer T.J., Kivitz A.J., Lipetz R.S., Sanders N., and Hee A. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum 53 (2005) 827-837
2. Rees D.D., Palmer R.M., and Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci U S A 86 (1989) 3375-3378
3. Moncada S., and Higgs E.A. The discovery of nitric oxide and its role in vascular biology. Br J Pharmacol 147 suppl (2006) S193-S201
4. Medical Dictionary for Regulatory Activities Terminology: Version 9.1 (2006), Maintenance and Support Services Organization, Reston, Virginia
5. Whelton A., White W.B., Bello A.E., Puma J.A., Fort J.G., and SUCCESS-VII Investigators. Effects of celecoxib and rofecoxib on blood pressure and edema in patients ≥65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 90 (2002) 959-963
6. Morgan T.O., Anderson A., and Bertram D. Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 13 (2000) 1161-1167
7. Muscara M.N., McKnight W., Del Soldato P., and Wallace J.L. Effect of a nitric oxide-releasing naproxen derivative on hypertension and gastric damage induced by chronic nitric oxide inhibition in the rat. Life Sci 62 (1998) 235-240
8. Lohmander L.S., McKeith D., Svensson O., Malmenas M., Bolin L., Kalla A., Genti G., Szechinski J., Ramos-Remus C., and STAR Multinational Study Group. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 64 (2005) 449-456
9. White W.B. Cardiovascular effects of the cyclooxygenase inhibitors. Hypertension 49 (2007) 408-418
10. Izhar M., Alausa T., Folker A., Hung E., and Bakris G.L. Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and Hispanics. Hypertension 43 (2004) 574-577
11. White W.B., Kent J., Taylor A., Verburg K.M., Lefkowith J.B., and Whelton A. Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 39 (2002) 929-934
12. Houston M.C., Weir M., Gray J., Ginsberg D., Szeto C., Kaihlenen P.M., Sugimoto D., Runde M., and Lefkowitz M. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 155 (1995) 1049-1054
13. Klassen D.K., Jane L.H., Young D.Y., and Peterson C.A. Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 8 (1995) 146-153
14. MacDonald T.M., Reginster J.Y., Littlejohn T.W., Richard D., Lheritier K., Krammer G., and Rebuli R. Effect on blood pressure of lumiracoxib versus ibuprofen in patients with osteoarthritis and controlled hypertension: a randomized trial. J Hypertens 26 (2008) 1695-1702
15. Pope J.E., Anderson J.J., and Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 153 (1993) 477-484
16. Johnson A.G., Nguyen T.V., and Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure?. A meta-analysis. Ann Intern Med 121 (1994) 289-300
17. Grover S.A., Coupal L., and Zowall H. Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: what are the benefits of avoiding blood pressure destabilization?. Hypertension 45 (2005) 92-97
18. White W.B. Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med 160 (2000) 149-150
19. Julius S., Kjeldsen S.E., Weber M., Brunner H.R., Ekman S., Hansson L., Hua T., Laragh J., McInnes G.T., Mitchell L., Plat F., Schork A., Smith B., Zanchetti A., and VALUE Trial Group. Outcomes in hypertensive patients at high CV risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 363 (2004) 2022-2031
20. McInnis N.H., Fodor G., Lum-Kwong M.M., and Leenan F.H. Antihypertensive medication use and blood pressure control: a community-based cross-sectional survey (ON-BP). Am J Hypertens 21 (2008) 1210-1215